Every lab that handles a pathogen is operating somewhere on a four-step ladder. At the bottom, undergraduates pipette harmless E. coli on an open bench. At the top, scientists in positive-pressure suits work on Ebola behind airlocks and pass-through autoclaves. The ladder has a name: biosafety level, BSL-1 through BSL-4.
Roughly 60 BSL-4 labs exist worldwide, and the count is growing. The rules shape how fast outbreaks can be characterized, where vaccine work happens, and which countries can study their own emerging viruses. This post is part of pandemic preparedness 101 and pairs with novel pathogens explained, which covers the biology that drives BSL designations.
Key Takeaways
- BSL-1 through BSL-4 rank labs by agent risk and containment required.
- BSL-1 is ordinary microbiology with non-pathogens. BSL-2 covers most clinical work, including hepatitis B, HIV in cell culture, Salmonella, and S. aureus.
- BSL-3 is the level for serious airborne disease: tuberculosis, SARS-CoV-2, MERS-CoV, Yersinia pestis, West Nile, Coxiella burnetii. Negative pressure, all work in a biosafety cabinet.
- BSL-4 is reserved for life-threatening pathogens with no available treatment: Ebola, Marburg, Lassa, Nipah, smallpox stocks, Crimean-Congo hemorrhagic fever.
- About 60 BSL-4 labs operate worldwide, including USAMRIID, CDC Atlanta, Galveston National Lab, Wuhan Institute of Virology, and Porton Down.
- Animal versions (ABSL-1 to ABSL-4) parallel the same structure for animal research.
What are biosafety levels?
Biosafety levels are a four-tier classification (BSL-1, BSL-2, BSL-3, BSL-4) that match the hazard of a microorganism to the lab containment required to work with it safely. Each level adds training, practices, primary barriers (PPE and biosafety cabinets), and secondary barriers (the building itself). The system was formalized by the CDC and NIH in the Biosafety in Microbiological and Biomedical Laboratories (BMBL) manual, now in its 6th edition (2020).
The framework is risk-based, not pathogen-list-based. The same organism can be handled at different levels depending on the procedure. Aerosol-generating work, animal challenge studies, or culture concentration push the required level up. The BMBL gives guidance; the actual level is set by the institution's biosafety committee.
The four levels stack as follows.
| Level | Agent characteristics | Containment | Example pathogens |
|---|---|---|---|
| BSL-1 | Not known to cause disease in healthy adults | Open bench, standard practices, no special equipment | E. coli K-12, Bacillus subtilis, non-pathogenic yeast |
| BSL-2 | Moderate risk, mainly via ingestion or skin/mucous-membrane exposure | Biosafety cabinet for aerosol work, PPE, restricted access | HIV (in cell culture), hepatitis B and C, Salmonella, S. aureus, most clinical specimens |
| BSL-3 | Serious or potentially lethal disease via inhalation | Negative-pressure facility, controlled access, respirators, all work in BSC | M. tuberculosis, SARS-CoV-2, MERS-CoV, Yersinia pestis, West Nile, Coxiella burnetii |
| BSL-4 | Life-threatening, often no treatment or vaccine, high transmissibility risk | Positive-pressure suits or Class III BSCs, airlocks, pass-through autoclave, dedicated HEPA supply and exhaust | Ebola, Marburg, Lassa, Nipah, Hendra, Crimean-Congo, smallpox stocks |
Animal research uses parallel ABSL-1 through ABSL-4 designations with similar containment philosophy adapted for the additional risks of working with infected animals.
What pathogens go in BSL-1 and BSL-2?
BSL-1 covers organisms not known to cause disease in healthy adults. Standard benches with no biosafety cabinet, basic PPE (lab coat, gloves, eye protection), handwashing, and waste decontamination are sufficient. Teaching labs working with E. coli K-12, Bacillus subtilis, baker's yeast, or harmless soil bacteria run at this level.
BSL-2 is where most clinical, hospital, and university microbiology happens. The agents cause real disease but transmission is dominated by ingestion, mucous-membrane exposure, or percutaneous injury rather than aerosols. Hepatitis B and C, HIV (in cell culture), Salmonella, Staphylococcus aureus, Streptococcus pneumoniae, Toxoplasma, and most clinical diagnostic specimens fall here. Containment adds a Class II biosafety cabinet for splash or aerosol-generating work, restricted access, biohazard signage, and sharps protocols.
What is BSL-3, and why do we have so much TB and SARS-CoV-2 research at this level?
BSL-3 is the level for indigenous or exotic agents that cause serious or potentially lethal disease through inhalation. Agents include Mycobacterium tuberculosis, SARS-CoV-2, MERS-CoV, Yersinia pestis (plague), Coxiella burnetii (Q fever), West Nile virus, Francisella tularensis, and Bacillus anthracis.
The facility itself becomes a containment device. BSL-3 labs operate at negative pressure, so air flows in rather than out. Access goes through two sets of self-closing doors that form an anteroom. All work with infectious material happens inside a Class II biosafety cabinet. Personnel wear N95 or PAPR respirators, solid-front gowns, and double gloves. Exhaust is HEPA-filtered, and staff have baseline serology and post-exposure protocols.
TB and SARS-CoV-2 dominate BSL-3 census numbers because of volume. TB is endemic in much of the world; reference labs culture thousands of isolates a year. SARS-CoV-2 work expanded BSL-3 capacity sharply between 2020 and 2023. Diagnostic PCR on inactivated samples can run at BSL-2, but culture and animal challenge require BSL-3.
What is BSL-4, and which pathogens require it?
BSL-4 is the highest containment level, reserved for dangerous and exotic agents that cause life-threatening disease, are transmitted by aerosols, and have no available treatment. The list is short: filoviruses (Ebola, Marburg), hemorrhagic arenaviruses (Lassa, Junin, Machupo, Sabia), henipaviruses (Nipah, Hendra), Crimean-Congo hemorrhagic fever virus, tick-borne encephalitis complex agents, and the two known smallpox stocks at CDC Atlanta and Russia's VECTOR institute.
Two facility designs deliver BSL-4 containment. The "suit lab" puts workers in fully encapsulated positive-pressure suits with their own air supply; any breach pushes air outward, away from the worker. The "cabinet lab" uses a Class III biosafety cabinet (a sealed glove box) for all work, with the worker outside in a normal room. Both designs include airlocks, chemical showers, pass-through autoclaves, dedicated HEPA supply and exhaust, and effluent decontamination.
Roughly 60 BSL-4 facilities exist worldwide. Notable ones include USAMRIID at Fort Detrick, CDC Atlanta, the NIH Integrated Research Facility, the Galveston National Laboratory, the Wuhan Institute of Virology, the UK Health Security Agency facility at Porton Down, Canada's National Microbiology Laboratory in Winnipeg, the Bernhard Nocht Institute in Hamburg, and the Australian Centre for Disease Preparedness in Geelong.
How do BSL designations affect outbreak response?
Containment requirements shape who can do what during an outbreak. Diagnostic testing on inactivated samples can usually run at BSL-2. Viral culture, sequencing of intact virus, neutralization assays, and animal challenge studies require the higher levels. For a BSL-4 pathogen like Lassa or Ebola, most of the planet has no in-country capacity to do the laboratory work needed to characterize an outbreak strain.
During the 2014 to 2016 West Africa Ebola outbreak, Liberia, Sierra Leone, and Guinea had no BSL-4 capacity. Specimens flowed to USAMRIID, the Bernhard Nocht Institute, Public Health England, Senegal's Institut Pasteur, and mobile labs deployed by the European Mobile Laboratory Project. The pattern repeated for Marburg outbreaks in Equatorial Guinea and Tanzania in 2023. Building regional capacity, including ABSL-4 for animal model work, is one of the most cited gaps in global outbreak response.
A handheld PCR cartridge can run almost anywhere, but cell culture confirmation for a suspected BSL-4 pathogen requires international shipping. For the novel pathogens on the WHO Blueprint priority list, this is the practical bottleneck.
What about gain-of-function research?
Gain-of-function (GOF) research is laboratory work that increases a pathogen's transmissibility, host range, or virulence. Some is mundane: cell-culture adaptation that improves yield. Some is contentious: experiments that engineer or select for properties giving a pathogen pandemic potential. The contentious subset has its own regulatory regime sitting on top of the BSL system.
In 2014, the US imposed a moratorium on federal funding for GOF research on influenza, SARS, and MERS coronaviruses after biosafety incidents and a public letter from the Cambridge Working Group of more than 200 scientists. The moratorium was lifted in 2017 and replaced with the P3CO framework (Potential Pandemic Pathogens Care and Oversight), which routes proposals through an HHS review committee. The framework was tightened in 2024 after congressional and inspector-general criticism.
GOF work that produces a pathogen with pandemic potential requires biosafety beyond the standard BSL designation: typically BSL-3 or BSL-4 with additional procedural and access controls, sometimes labeled BSL-3+. The BSL system tells you what containment matches a pathogen as it exists in nature. The P3CO framework tells you whether the experiment that creates a more dangerous version of that pathogen should happen at all.
FAQ
Why is HIV worked on at BSL-2 but tuberculosis at BSL-3?
HIV transmits through blood and sexual contact, not aerosols. Cell-culture work with HIV runs safely at BSL-2 with biosafety cabinet use and sharps precautions. M. tuberculosis transmits through inhaled droplet nuclei, so any procedure that could generate aerosols, including routine subculture of clinical isolates, demands negative-pressure containment and respirators. The route of transmission matters as much as severity.
Where are the BSL-4 labs in the United States?
The main US BSL-4 facilities are USAMRIID at Fort Detrick (Maryland), CDC Atlanta, the NIH Integrated Research Facility, the Galveston National Laboratory (Texas), the Texas Biomedical Research Institute, the National Bio and Agro-Defense Facility in Manhattan, Kansas, and Boston University's NEIDL.
Is the Wuhan Institute of Virology really BSL-4?
Yes, since 2018. The WIV operates the only BSL-4 facility in mainland China, built with French design assistance, alongside BSL-3 and BSL-2 suites. Whether SARS-CoV-2 work was done at BSL-2, BSL-3, or BSL-4 at the WIV before the COVID-19 pandemic, and what the implications are for origin questions, has been the subject of ongoing US intelligence community and congressional review since 2020.
Can a country handle Ebola at BSL-3 if it has no BSL-4?
Clinical care of Ebola patients is done in standard hospital isolation with airborne and contact precautions, not BSL-4. Inactivated diagnostic samples (RNA extracts, killed virus) can be tested at BSL-2 or BSL-3 depending on national rules. What requires BSL-4 is live virus culture, animal challenge, and high-titer manipulation. So a country with no BSL-4 can still test, treat, and contain Ebola; it just cannot do the laboratory research on intact virus.
Are biosafety levels the same as biosecurity levels?
No. Biosafety addresses accidental release and worker protection; biosecurity addresses deliberate misuse, theft, or sabotage of pathogens. The two overlap in practice (BSL-4 facilities also have strict biosecurity controls under the US Federal Select Agent Program), but they are governed by separate regulations. A pathogen can be a high-biosafety hazard without being a select agent, and vice versa.